Ryan T Morse1, Rohit G Ganju1, Mindi J TenNapel1, Prakash Neupane2, Kiran Kakarala3, Yelizaveta Shnayder3, Allen M Chen4, Christopher E Lominska1. 1. Department of Radiation Oncology, University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas. 2. Department of Medical Oncology, University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas. 3. Department of Otolaryngology, University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas. 4. Department of Radiation Oncology, University of California, Irvine, UC Irvine School of Medicine, Orange, California.
Abstract
BACKGROUND: Triweekly high-dose cisplatin (100 mg/m2 ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m2 with alternative weekly 40 mg/m2 and weekly <40 mg/m2 cisplatin regimens. METHODS: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression-free survival. RESULTS: Cisplatin weekly <40 mg/m2 showed inferior OS outcomes when compared to weekly 40 mg/m2 (P = 0.084) and triweekly 100 mg/m2 (P = 0.04) regimens. CONCLUSION: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m2 , suggesting the inferiority of low-dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m2 chemotherapy regimens.
BACKGROUND: Triweekly high-dose cisplatin (100 mg/m2 ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m2 with alternative weekly 40 mg/m2 and weekly <40 mg/m2 cisplatin regimens. METHODS: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression-free survival. RESULTS:Cisplatin weekly <40 mg/m2 showed inferior OS outcomes when compared to weekly 40 mg/m2 (P = 0.084) and triweekly 100 mg/m2 (P = 0.04) regimens. CONCLUSION: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m2 , suggesting the inferiority of low-dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m2 chemotherapy regimens.
Authors: Alyson L Essex; Fabrizio Pin; Joshua R Huot; Lynda F Bonewald; Lilian I Plotkin; Andrea Bonetto Journal: Front Endocrinol (Lausanne) Date: 2019-11-19 Impact factor: 5.555
Authors: Ryan T Hughes; Mercedes Porosnicu; Beverly J Levine; Thomas W Lycan; Rachel F Shenker; Bart A Frizzell; Kathryn M Greven Journal: J Med Imaging Radiat Oncol Date: 2021-07-26 Impact factor: 1.667